TMED - ETF AI Analysis
Top Page
T. Rowe Price Health Care ETF (TMED)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past few months, showing solid recent momentum.
Leading Health Care Names
Top holdings like Eli Lilly, UnitedHealth, and Gilead have shown positive performance, helping support the fund’s returns.
Focused Health Care Exposure
The fund is heavily invested in health care companies, which can benefit investors who want targeted exposure to this sector.
Negative Factors
High Stock Concentration
A small number of holdings, especially Eli Lilly, make up a large share of the portfolio, increasing the impact if these stocks struggle.
Many Top Holdings Are Weak
Several major positions, including Thermo Fisher, Intuitive Surgical, and others, have shown weak performance this year, which could drag on future returns.
Limited Geographic Diversification
Almost all assets are invested in U.S. companies, offering little protection if the U.S. market or health care sector faces a downturn.
TMED vs. SPDR S&P 500 ETF (SPY)
AUM32.23M
RegionGlobal
Expense Ratio0.44%
Beta0.60
IssuerT. Rowe Price
Inception DateJun 11, 2025
Dividend Yield0.48%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,366
30 Day Avg. Volume7,985
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
49.85Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering107
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMED Summary
TMED is the T. Rowe Price Health Care ETF, an actively managed fund that focuses on health care companies rather than tracking a fixed index. It mainly holds U.S. health care stocks, including well-known names like Eli Lilly and UnitedHealth, along with drug makers, medical device firms, and health care service providers. Someone might invest in TMED to tap into the long-term growth of medical innovation and to diversify within the health care sector. However, because it is concentrated in health care, its value can go up or down sharply if that sector falls out of favor or faces regulation changes.
How much will it cost me?The T. Rowe Price Health Care ETF (TMED) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, with experts carefully selecting and adjusting the fund’s holdings to try to outperform traditional health care sector indices.
What would affect this ETF?The TMED ETF could benefit from advancements in biotechnology and medical innovation, as well as increasing global demand for health care services driven by aging populations and emerging markets. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact health care spending and the profitability of its top holdings. Additionally, fluctuations in interest rates could affect the broader market and investor sentiment toward health care stocks.
TMED Top 10 Holdings
TMED is leaning heavily on a few big health care names, with Eli Lilly as the flagship: despite some recent wobbling, it’s still a key engine for long-term gains. UnitedHealth has been rising over the year but has lost a bit of steam lately, while Thermo Fisher and Agilent are quietly climbing and helping steady the ship. On the flip side, Alnylam and Insulet have been lagging and act like a headwind. Overall, this is a globally focused but U.S.-dominated health care play, concentrated in pharma, biotech, and medical tools.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 11.18% | $3.59M | $1.05T | 47.70% | 72 Outperform | |
| Alnylam Pharma | 5.69% | $1.83M | $33.28B | -46.62% | 60 Neutral | |
| UnitedHealth | 5.51% | $1.77M | $340.27B | 7.54% | 72 Outperform | |
| Thermo Fisher | 3.79% | $1.22M | $225.48B | 27.19% | 72 Outperform | |
| Cencora | 3.28% | $1.06M | $61.36B | 6.30% | 70 Neutral | |
| Insulet | 3.14% | $1.01M | $9.15B | -61.39% | 70 Outperform | |
| Gilead Sciences | 3.12% | $1.00M | $178.21B | 25.46% | 78 Outperform | |
| Agilent | 2.78% | $893.50K | $41.42B | 19.22% | 73 Outperform | |
| Cytokinetics | 2.62% | $843.98K | $10.26B | 44.28% | 57 Neutral | |
| Elanco Animal Health | 2.61% | $838.98K | $11.58B | 25.04% | 69 Neutral |
TMED Technical Analysis
Neutral
―
Price Trends
34.92
Negative
33.19
Positive
31.44
Positive
Market Momentum
-0.29
Positive
37.87
Neutral
10.56
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMED, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 35.32, equal to the 50-day MA of 34.92, and equal to the 200-day MA of 31.44, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 37.87 is Neutral, neither overbought nor oversold. The STOCH value of 10.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TMED.
TMED Peer Comparison
Comparison Results
Performance Comparison
TMED
T. Rowe Price Health Care ETF
33.90
7.94
30.59%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents